Word

TETRAX

Status

Dead

Status Code

606

Status Date

Monday, January 15, 2024

Serial Number

97081506

Mark Type

4000

Filing Date

Tuesday, October 19, 2021

Published for Opposition

Tuesday, April 18, 2023

Abandoned Date

Monday, January 15, 2024

Trademark Owner History

SYNERGY IMT, INC. - Owner At Publication

Classifications

40 custom manufacture of therapeutic drugs, namely, custom manufacture of cell therapies and cancer therapies; Manufacture of pharmaceuticals, pharmaceutical ingredients, vaccines and antibodies for others

5 pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical products for the diagnosis, prevention and treatment of cancer; Antibodies being pharmaceutical preparations for the diagnosis, treatment and prevention of cancer, immune response disorders, genetic conditions, infectious diseases and vascular diseases; Vaccines; Pharmaceutical preparations for cell therapy; Preparations of blood extracted from humans or animals which have been adapted for medical or therapeutic purposes

1 biochemicals, namely, antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules for in vitro scientific or research use

42 custom design and engineering of antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Providing a bioinformatics platform as a service (PAAS) featuring computer software for developing antibody-derived antigen binding molecules and antibody-derived recombinant antigen binding molecules; Custom design and engineering of antibodies; Custom design and engineering of antigens; Antibody engineering; Biochemical research and development; Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Development and establishment of testing specifications and procedures in the field of biotechnology; Research and development in the pharmaceutical and biotechnology fields; Scientific research in the development of new cancer therapies; Scientific research in human and animal cell therapy; Platform as a service (PAAS) featuring computer software platforms for analysis of bioinformatic data

Trademark Events

Jan 16, 2024

Abandonment Notice E-Mailed - No Use Statement Filed

Jan 15, 2024

Abandonment - No Use Statement Filed

Jun 13, 2023

Noa E-Mailed - Sou Required From Applicant

Apr 18, 2023

Official Gazette Publication Confirmation E-Mailed

Apr 18, 2023

Published For Opposition

Mar 29, 2023

Notification Of Notice Of Publication E-Mailed

Mar 13, 2023

Approved For Pub - Principal Register

Mar 8, 2023

Examiner's Amendment Entered

Mar 8, 2023

Notification Of Examiners Amendment E-Mailed

Mar 8, 2023

Examiners Amendment E-Mailed

Mar 8, 2023

Examiners Amendment -Written

Aug 1, 2022

Notification Of Non-Final Action E-Mailed

Aug 1, 2022

Non-Final Action E-Mailed

Aug 1, 2022

Non-Final Action Written

Jul 26, 2022

Assigned To Examiner

Nov 5, 2021

New Application Office Supplied Data Entered

Oct 22, 2021

New Application Entered